Promonitor® is a product developed by Progenika and distributed worlwide. Please contact your local distributor to place an order.
|
|
Promonitor® kits | IVD Reference | RUO Reference |
Promonitor-IFX (infliximab levels)* | 5060230000 | 5060130000 |
Promonitor-Anti-IFX (anti-infliximab antibody levels)* | 5070230000 | 5070130000 |
Promonitor-ADL (adalimumab levels) | 5080230000 | 5080130000 |
Promonitor-Anti-ADL (anti-adalimumab antibody levels) | 5090230000 | 5090130000 |
Promonitor-ETN (etanercept levels)* | 5110230000 | 5110130000 |
Promonitor-Anti-ETN (anti-etanercept antibody levels) | 5120230000 | 5120130000 |
Promonitor-RTX (rituximab levels)* | 5130230000 | 5130130000 |
Promonitor-Anti-RTX (anti-rituximab antibody levels) | 5140230000 | 5140130000 |
Promonitor-GLM (golimumab levels) | 5200230000 | 5200130000 |
Promonitor-Anti-GLM (anti-golimumab antibody levels) | 5210230000 | 5210130000 |
Promonitor-VDZ (vedolizumab) | 5391530000 | 5391430000 |
Promonitor-Anti-VDZ (anti-vedolizumab antibody levels) | 5401530000 | 5401430000 |
Promonitor-UTK (ustekinumab levels) | In validation | 53714300DV |
Promonitor-Anti-UTK (anti-ustekinumab antibody levels) | In validation | 53814300DV |
*Promonitor-IFX (Refs. 5060230000/5060130000) and Promonitor-Anti-IFX (Refs. 5070230000/5070130000) are valid to monitor drug levels and anti-drug antibody levels of any biological drug which contains the active substance infliximab; that is the reference medicine Remicade® and any biosimilar drug like CT-P13 (Remsima® or Inflectra®) and SB2 (Flixabi®). Promonitor-RTX (5130230000/5130130000) is valid to monitor either the reference rituximab (MabThera®) or the biosimilar CT-P10 (Truxima®). Promonitor-ETN (Refs. 5110230000/5110130000) is valid to monitor drug levels of any biological drug which contains the active substance etanercept; that is the reference medicine Enbrel® and any biosimilar drug like SB4 (Benepali®) and Erelzi®. |
Drug and anti-drug antibody levels are also available as a Diagnostic Service. Patient samples for testing are collected according to a standard protocols and sent to Proteomika for analysis. Sample analysis is performed by trained personnel in authorized facilities. The referring clinic receives a detailed report via e-mail presenting patient-specific information on circulating drug levels and immune response to treatment in the context of clinical studies allowing easy interpretation of the test results.